Robert W. Baird Increases Twist Bioscience (NASDAQ:TWST) Price Target to $54.00

Twist Bioscience (NASDAQ:TWST) had its target price lifted by Robert W. Baird from $48.00 to $54.00 in a research note published on Tuesday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research analysts have also recently issued reports on TWST. Scotiabank increased their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. TD Cowen reaffirmed a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Barclays lowered their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Trading Down 1.4 %

Shares of TWST stock opened at $52.02 on Tuesday. Twist Bioscience has a 12-month low of $27.41 and a 12-month high of $60.90. The company has a market cap of $3.09 billion, a price-to-earnings ratio of -14.45 and a beta of 1.87. The stock has a 50 day simple moving average of $48.63 and a 200-day simple moving average of $46.21.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same quarter last year, the company earned ($0.75) earnings per share. Twist Bioscience’s quarterly revenue was up 24.1% compared to the same quarter last year. On average, equities analysts forecast that Twist Bioscience will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 2,422 shares of Twist Bioscience stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $50.17, for a total value of $121,511.74. Following the completion of the sale, the chief operating officer now owns 272,044 shares in the company, valued at $13,648,447.48. The trade was a 0.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares in the company, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,707 shares of company stock worth $2,343,623 over the last ninety days. 3.01% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of TWST. Thrivent Financial for Lutherans acquired a new position in shares of Twist Bioscience in the 3rd quarter valued at $43,992,000. State Street Corp boosted its holdings in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after acquiring an additional 526,028 shares during the last quarter. Wellington Management Group LLP grew its position in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the period. Jennison Associates LLC grew its position in Twist Bioscience by 80.2% during the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after acquiring an additional 302,884 shares during the period. Finally, ARK Investment Management LLC increased its stake in Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after acquiring an additional 237,772 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.